Want to see TSE:AIML full AI Analyst Report?
Top Page
Aiml Resources
(AIML)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.04
▼(-24.00% Downside)
Action:Reiterated
Date:08/30/26
The overall score is constrained primarily by very weak financial performance (declining revenue, worsening profitability, negative equity, and persistent cash burn). Technical indicators add only modest support due to low momentum readings and price weakness versus key moving averages, while valuation is not compelling given the negative P/E and no provided dividend yield.
Positive Factors
EPS Growth
Positive EPS growth provides a limited indication that per-share earnings metrics improved despite the company remaining loss-making. Sustaining this improvement could support future recovery, although the latest annual loss and broader operating deterioration substantially weaken its current significance.
Negative Factors
Sharp Revenue Decline
The steep revenue contraction signals weakening demand, customer traction, or commercial execution and reduces operating scale. Lower revenue makes it harder to absorb fixed costs, rebuild margins, and reach sustainable profitability over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
EPS Growth
Positive EPS growth provides a limited indication that per-share earnings metrics improved despite the company remaining loss-making. Sustaining this improvement could support future recovery, although the latest annual loss and broader operating deterioration substantially weaken its current significance.
Read all positive factors
Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$10.16M
Dividend YieldN/A
Average Volume (3M)270.75K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue Growth-50.36%
EPS Growth3.93%
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding253,987,750
10 Day Avg. Volume393,540
30 Day Avg. Volume270,747
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-12.15
Price to Sales (P/S)114.91
P/FCF Ratio-1.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aiml Resources Business Overview & Revenue Model
Company Description
Operating within the digital healthcare sector, AI/ML Innovations Inc. harnesses the power of artificial intelligence (AI) and machine learning (ML). The company's central offering is a patent-pending system for personal health monitoring and mana...
Aiml Resources Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
16
Very Negative
| Breakdown | Apr 2026 | Jul 2025 | Jul 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 83.06K | 167.31K | 600.14K | 487.50K | 65.41K |
| Gross Profit | -2.75M | 162.81K | 294.86K | 466.01K | 65.41K |
| EBITDA | -6.39M | -4.85M | -1.67M | -1.36M | -3.42M |
| Net Income | -6.36M | -4.59M | -3.29M | -1.42M | -3.17M |
Balance Sheet | |||||
| Total Assets | 2.07M | 3.41M | 329.69K | 1.51M | 2.04M |
| Cash, Cash Equivalents and Short-Term Investments | 257.77K | 2.00M | 216.86K | 14.56K | 525.24K |
| Total Debt | 962.20K | 198.19K | 197.72K | 859.98K | 261.34K |
| Total Liabilities | 2.89M | 855.77K | 1.54M | 1.79M | 1.55M |
| Stockholders Equity | -785.25K | 2.60M | -1.17M | -247.46K | 1.08M |
Cash Flow | |||||
| Free Cash Flow | -5.41M | -3.99M | -1.64M | -634.28K | -3.02M |
| Operating Cash Flow | -5.41M | -3.99M | -1.64M | -634.28K | -3.02M |
| Investing Cash Flow | -4.67K | -1.15K | -325.98K | -210.64K | -1.14M |
| Financing Cash Flow | 3.67M | 5.78M | 2.16M | 374.37K | 1.27M |
Aiml Resources Technical Analysis
Negative
0.05
Price Trends
0.04
Negative
0.05
Negative
0.04
Negative
Market Momentum
>-0.01
Positive
36.60
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIML, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.60 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AIML.
Aiml Resources Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$57.20M | -11.50 | 9999.00% | ― | -36.92% | 13.03% | |
45 Neutral | C$12.90M | -1.99 | 64.52% | ― | 7.63% | -106.03% | |
45 Neutral | C$6.58M | -3.23 | 739.84% | ― | ― | -28.35% | |
42 Neutral | C$11.23M | -3.24 | 6239.15% | ― | ― | 68.00% | |
41 Neutral | C$10.16M | -1.49 | -1152.00% | ― | -50.36% | 3.93% | |
41 Neutral | C$4.21M | -1.45 | 184.91% | ― | ― | 43.30% |
* Healthcare Sector Average
TSE:AIML
Aiml Resources
0.04
0.00
0.00%
TSE:ADK
Diagnos
0.48
0.21
82.69%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.45
-0.05
-11.00%
TSE:UDOC
UniDoc Health Corp
0.13
-0.07
-35.00%
TSE:NARA
PanGenomic Health, Inc. Class A
0.30
-2.06
-87.29%
TSE:DMED
DiagnaMed Holdings Corp.
0.05
-0.04
-41.18%
Aiml Resources Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
NeuralCloud to Pilot AI ECG Platforms with Island Mobile Cardiology Testing
Positive
Aug 18, 2026
NeuralCloud Solutions Inc., a subsidiary of AI/ML Innovations Inc., has signed a non-binding commercial term sheet with Island Mobile Cardiology Testing to run a pilot of its MaxYield and CardioYield platforms in a mobile Holter monitoring workflo...
Business Operations and StrategyPrivate Placements and Financing
AI/ML Innovations Plans $2 Million Private Placement to Fund Digital Health Expansion
Positive
Aug 14, 2026
AI/ML Innovations Inc., a global AI-driven digital health company, develops proprietary platforms that apply neural networks and deep learning to complex biometric data. Its technology is designed to generate actionable clinical insights that supp...
Business Operations and StrategyRegulatory Filings and Compliance
NeuralCloud Gains ISO 13485 MDSAP Certification for ECG AI Medical Software
Positive
Aug 11, 2026
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has obtained ISO 13485:2016 certification under the Medical Device Single Audit Program for its quality management system covering the design, development, production, and distribution of E...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.